NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









TRIANA Biomedicines

TRIANA Biomedicines

Private
Lexington, MassachusettsHealthcare & Life Scienceshttps://trianabio.com/

Last Round

Series B

Dec 3, 2025

Est. Valuation

$258M

Total Funding Raised

$350M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

TRIANA Biomedicines is a biotechnology company that discovers and develops molecular glue therapeutics to target and degrade disease-causing proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

molecular gluetargeted protein degradationTPDsmall-molecule therapeuticsoncologydrug discoveryALK-positivenon-small cell lung cancerNSCLCprotein degraderundruggable targetsclinical-stage biotechbiopharmaE3 ligaseprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TRIANA Biomedicines Comps

Public and private peers based on sector, stage, and business model.

TRIANA Biomedicines comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

TRIANA Biomedicines Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 3, 2025
Series BDec 3, 2024
Series AApr 6, 2022

Key People

Founding team and executive leadership

Patrick Trojer

Chief Executive Officer President

Executive Team

TRIANA Biomedicines Investors

Notable investors and investment history

TRIANA Biomedicines investors
InvestorRounds
Surveyor CapitalSeries B, Series A
RA Capital ManagementSeries B, Seed, Series A
Finchley Healthcare VenturesSeries B
Invus OpportunitiesSeries B
Logos CapitalSeries A
AccompliceSeries B
CitadelSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    Monthly visitors increased 149% MoM, reaching 6.2K.

  • Apr 15, 2026

    Presenting candidate TRI-611 at AACR Annual Meeting 2026.

TRIANA Biomedicines Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TRIANA Biomedicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TRIANA Biomedicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersLexington, Massachusetts
Employee Range62
Year Founded2019
Last FundingDec 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.